Loading…

Initial results from the PHEFREE longitudinal natural history study: Cross-sectional observations in a cohort of individuals with phenylalanine hydroxylase (PAH) deficiency

Over fifty years have passed since the last large scale longitudinal study of individuals with PAH deficiency in the U.S. Since then, there have been significant changes in terms of treatment recommendations as well as treatment options. The Phenylalanine Families and Researchers Exploring Evidence...

Full description

Saved in:
Bibliographic Details
Published in:Molecular genetics and metabolism 2024-09, Vol.143 (1-2), p.108541, Article 108541
Main Authors: Christ, Shawn E., Arnold, Georgianne, Lichter-Konecki, Uta, Berry, Gerard T., Grange, Dorothy K., Harding, Cary O., Jurecki, Elaina, Levy, Harvey, Longo, Nicola, Morotti, Hadley, Sacharow, Stephanie, Thomas, Janet, White, Desiree A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over fifty years have passed since the last large scale longitudinal study of individuals with PAH deficiency in the U.S. Since then, there have been significant changes in terms of treatment recommendations as well as treatment options. The Phenylalanine Families and Researchers Exploring Evidence (PHEFREE) Consortium was recently established to collect a more up-to-date and extensive longitudinal natural history in individuals with phenylketonuria across the lifespan. In the present paper, we describe the structure and methods of the PHEFREE longitudinal study protocol and report cross-sectional data from an initial sample of 73 individuals (5 months to 54 years of age) with PAH deficiency who have enrolled. Looking forward, the study holds the promise for advancing the field on several fronts including the validation of novel neurocognitive tools for assessment in individuals with PKU as well as evaluation of the long-term effects of changes in metabolic control (e.g., effects of Phe-lowering therapies) on outcome.
ISSN:1096-7192
1096-7206
1096-7206
DOI:10.1016/j.ymgme.2024.108541